TARGETING OF CYTOKINE ANTAGONISTS

The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor s...

Full description

Saved in:
Bibliographic Details
Main Authors PAUL, FRANCIANE, GARCIN, GENEVIÈVE, UZÉ, GILLES, TAVERNIER, JAN, BORDAT, YANN, ZABEAU, LENNART
Format Patent
LanguageEnglish
French
German
Published 25.05.2016
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
Bibliography:Application Number: EP20140734166